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Abstract 
Recently, the need for health care services has increased gradually and the limitations in sources allocated for this 
area have been recognized. Moving from this fact, it has gained a supreme importance to determine what health 
programs or technologies will be given priority. According to Danzon (Reference pricing: theory and evidence, refer-
ence pricing and pharmaceutical policy: perspectives on economics and innovation, springer, New York, pp 86–126, 
2001), arrangements towards controlling the expenses through price and profit controls, reimbursement methods 
and incentives have recently gained wide currency. This present study examines; along with the current situation 
in Turkey, pharmaceutical pricing methods, reimbursement methods and basic health indicators, within the scope 
of changing pharmaceutical policies, in Turkey, the EU countries which Turkey takes as reference and the United 
Kingdom, the implementations of which are of utmost importance for other countries. Upon the research conducted, 
it was detected that the pharmaceutical pricing in Turkey has been performed on the basis of the reference pricing 
system that takes Italy, Portugal, Spain, Greece and France as reference. The regulations regarding the reimbursement 
process are determined by SSI. For Turkey’s case; pricing and reimbursement system has been changed numerous 
times and the discount rates has incrementally risen. In pricing, on the other hand, during this period companies 
faced with difficulties in economic terms because of the fact that price discount of high rates are implemented over 
the reference price and that the European currency of Euro is determined as 70% of previous year average Euro sales 
rate which is 2,1166 for the year 2016. Each country has specific regulations and pricing and reimbursement policies 
of medicines based on economic situation, reimbursement methods and market size. The aim of pricing and reim-
bursement systems are reaching more efficient and sustainable healthcare systems.
Keywords: European Union pharmaceutical pricing systems, Health policy, Pharmaceutical pricing, Reference 
pricing, Reimbursement
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Background
As an important part of health service delivery, pharma-
ceutics is an industrial branch that produces simple or 
compound pharmaceutical forms within the framewoks 
of pharmaceutical technology and in compliance with the 
scientific standards from chemicals of synthetic, vegetal, 
animal and biological origin to be used for therapeutic, 
preventive and nutritive purposes in industrial, human 
and veterinary medicine (DPT 2001).
In its World Drug Report published in 2011, WHO 
states that the disease load of countries has shifted from 
acute diseases to chronic diseases. For this reason, difficul-
ties are experienced in supply of medicines, and medicine 
utilization is also affected. While the size of pharmaceu-
tical industry was 731 billion dollars in 2007, this Fig.  1 
increased to 965 billion dollars in 2011 (SCRIP100 2014), 
over 1.000 billion for 2015 and expected to be 1.400 bil-
lion dollars by 2019 (Deloitte 2016).
Recently, the need for health services has increased 
gradually and the limitations in sources allocated for this 
area have been recognized. Moving from this fact, it has 
gained a supreme importance to determine what health 
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programs or technologies will be given priority. Accord-
ing to Danzon (2001), arrangements towards controlling 
the expenses through price and profit controls, reim-
bursement methods and incentives have recently gained 
wide currency. Despite those were the main reasons of 
health refoms, there are also other reasons that are related 
to the improvements in social and health areas to lead to 
the generation of new reforms. Governments started to 
search actions to decrease health and education expendi-
tures because of financial crises that occurred by end of 
1970s. With the separation of service providers and ser-
vice funding in the health system, and the development 
of policies aimed at restraining public expenditure, it 
has been planned to minimize presence of public sector 
in both structures (Çaliskan 2009). The most commonly 
used method to bring pharmaceutical expenditures under 
control is the reference pricing system, which is used in 
numerous countries. The reference pricing system is the 
determination of the ceiling price of reimbursement for 
a certain group of medicines by the payer organization 
or insurance company. It is assumed that such a practice 
concerning medicines will lead to a decrease in medicine 
expenditures as medicine prices decrease (Çaliskan 2008).
While innovation in the pharmaceutical industry is 
usually welcomed by all stakeholders, it inevitably comes 
at the expense of having higher medicine prices and 
growing health-related expenditures (Rapple et al. 2010).
Global growth expected to be 5–8% by 2019 and 
reaches 1.300 billion US dollars, growth expected to be 
11–14% in Turkey (IMS 2015) (Fig. 2).
Developed markets CAGR 
2015–2019 (%)
Pharmerging markets CAGR 
2015–2019 (%)
US 6 to 9 Tier 1 (China) 6 to 9
Japan 0 to 3 Tier 2 9 to 12
Developed markets CAGR 
2015–2019 (%)
Pharmerging markets CAGR 
2015–2019 (%)
Germany 2 to 5 Brasil 10 to 13
UK 4 to 7 India 11 to 14
France −2 to 1 Russia 6 to 9
Italy 3 to 6 Tier 3 4 to 7
Canada 3 to 6 Turkey 11 to 14
Spain 2 to 5
Developed 4 to 7 Pharmerging 6 to 9
Source: IMS Market Prognosis Sept. 2015; at ex-manu-
facturer price level, without rebates and discounts
Pricing of pharmaceuticals and reimbursement has 
always important argument for countries. Pricing and 
reimbursement systems are closely linked to the realisa-
tion of European policy objectives such as the internal 
market, pharmaceutical competitiveness, sustainable 
research and development, and the protection of human 
health. Each country uses different schemes and policies, 
adapted to its own economic and health needs. These 
national systems are regularly reviewed or adapted in 
order to take account of political priorities, market evo-
lutions, and patients’ needs. The variety of healthcare 
and social security systems in the EU has an impact on 
the pharmaceutical industry, wholesalers, pharmacists, 
doctors, health insurers, and patients.Our article aims 
to show pricing and reimbursement systems in different 
countries. (European Union 2016).
One of the main driven pricing methods for pharma-
ceuticals are external reference pricing and internal ref-
erence pricing. External reference pricing (International 
price comparison); the practice of using the price(s) of a 
medicinal product in one or several countries in order to 
derive a benchmark or reference price for the purposes of 
setting or negotiating the price of the product in a given 
country.
Fig. 1 Global pharma segment sales Source: DTTL Life Sciences and Health Care Industry Group analysis of EIU data
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Internal reference pricing; commonly employed in 
EU countries as a means to regulate out-of-patent drug 
prices. Describes the practice of setting the price to be 
paid by public payers by comparing prices of equiva-
lent or similar products in a chemical, pharmacological 
or therapeutic group.c The ‘reference price’ applies to 
all pharmaceuticals within the corresponding group of 
products (Ruggeri and Nolte 2013).
Methods
This study was conducted with a descriptive method. 
The main tool of the study is implemented regulations 
of pharmaceutical pricing and reimbursement in Tur-
key, Italy, France, Portugal, Spain, Greece and United 
Kingdom. 5 Countries (Italy, France, Portugal, Spain, 
Greece) selected based on reference countries on pric-
ing of Turkey and UK selected with reason of one of the 
leading country on health policy. Data sources consist of 
Guidelines of Health Authorities and web pages, related 
articles, reports, other guidelines and laws and directives. 
Data are limited to 2015 April for countries mentioned in 
the article and June 2016 for Turkey.
Results
As shown in Table 2, there are differences in reimburse-
ment rates of comparison countries. While in France, 
Spain and Italy basically the reimbursement rates are 
set according to medical and economic evaluations, in 
UK free pricing is applied. By conducting margin con-
trol, however, a price intervention is carried out with 
direct control for the drugs that exceed the expected cost 
determined by PPRS agreements or that do not provide 
the expected benefit with their therapeutic effectiveness. 
While Portugal set reimbursement rates according to 
disease groups, Turkey and Greece apply the same con-
trol method for all drugs and pay lower than the defined 
lowest reference price in reimbursement system. Price 
comparison with other countries such as internal or/and 
external reference pricing is a criterion for all countries 
but in Turkey and Greece, it is the main criterion and 
the ceiling price is determined on the basis of the low-
est price in other countries. A lower price may be defined 
upon the request of manufacturer.
Pricing is basically processed by using 3 different 
methods
  • Free Pricing (Germany, The Netherlands, Denmark)
  • Direct Price Controls (France, Italy, Portugal, Greece, 
Spain, Turkey, Belgium)
  • Margin Controls (UK)
As shown in Tables 1 and 2 medicines has free pricing 
in UK but the prices are controlled through margin con-
trols. On the other hand, all other countries examined 
in our study apply direct price controls. France and Italy 
define prices upon negotiations with companies. Prices 
are not determined only with upon effectiveness and 
comparisons with other countries. In price determina-
tion, there are other factors considered such as produc-
tion costs, therapeutic efficiency, R&D expenditures, sale 
amounts, advertising costs and contribution to the econ-
omy of the country (Balçik and Karsavuran 2012).
In Italy, Average Europe Price is taken into considera-
tion while the prices are determined, but other factors 
mentioned above has impact on pricing decisions as well. 
Price comparisons are important for all the reviewed 
countries except UK, but this condition is not the sole 
criterion for other countries reviewed in our study 
except Turkey and Greece. Contribution margin and pri-
vate health insurances exist in all countries. Turkey and 
Greece takes minimum price as reference whereas Portu-
gal takes the average of the lowest 3 prices while defining 
prices. Price discounts are applied at variable rates in all 
countries. These discounts may continue to be applied in 
accordance with the changes occurring in yearly budgets 
(Tables 3, 4).
Social Security Institution (SSI) is payer and decision 
taking body for drug reimbursement. Discount rates 
applies on ex-factory prices as shown below and deter-
mine the reimbursement price.
Discussion
Recently pharma industry is a global industry that has 
the highest R&D potential. On one hand discovery of 
new molecules for specific and malignant diseases, and 
Fig. 2 Expected growth rate Source: IMS Market Prognosis Sept. 2015; 
at ex-manufacturer price level, without rebates and discounts
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the transformation of extended life expectancy into a 
better quality of life on the other, cross-border competi-
tion of global economy, increasing state intervention and 
control, leads to differentiation of pharma industry from 
other industries (TOBB 2008).
The starting point of drug policy determination is 
defining the target. This varies according to the income 
level each country. On the other hand, while defining this 
policies it should be noted that pharmaceutical innova-
tion saved millions of life and prolonged life expectancy 
during the past century (TİTCK 2014).
When pricing and reimbursement system is reviewed 
for Turkey and other countries in our study; it can be seen 
that each country has its own special conditions. While 
Turkey has some similarities with France, Greece, Italy 
and Spain with respect to pricing and reimbursement, 
it has significant differences from UK pricing and reim-
bursement system. In UK, pricing and reimbursement 
process go hand in hand and there is a margin control-
based system existing.
Margin control-based system used in the UK; describes 
a profit framework which is negotiated periodically 
between the Department of Health and the pharmaceu-
tical industry (Pharmaceutical Price Regulation Scheme, 
PPRS) (Ruggeri and Nolte 2013).
Since the PPRS is not a guaranteed profit scheme, com-
panies should not be penalised if they introduce a new, 
clinically and cost effective medicine which finds high 
acceptance by patients and prescribers. Equally, compa-
nies are not guaranteed a continuing profit level if sales 
decline under normal commercial circumstances. In rec-
ognition of this, the PPRS provides an element of flexibil-
ity in assessing company profitability. This is called the 
Margin of Tolerance (MOT).
The 2014 scheme builds on previous measures in this 
regard. A company may be permitted to retain up to 50% 
Table 1 Comparison of pricing methods in Turkey and certain other countries (Mossialos et al. 2004)
Country Market Direct price 
controls





France Original Yes Yes No No
Generic No Yes No Yes
Greece Original Yes Yes No Yes
Generic Yes Yes No Yes
Italy Original Yes Yes No No
Generic No Yes No Yes
Portugal Original Yes Yes No No
Generic No Yes No Yes
Spain Original Yes Yes No No
Generic No Yes No Yes
United Kingdom Original No No Yes Available for drugs excluded from PPRS
Generic Yes No No Available for drugs excluded from PPRS
Turkey Original Yes Yes No Yes
Generic Yes Yes No Yes
Table 2 Reimbursement systems in Turkey and certain other countries
Country Reimbursement levels Generic—original 
difference




France Major, moderate, weak N/A No reimbursement for non-prescription drugs Available
Greece 0, 10 and 25% Available No reimbursement for non-prescription drugs N/A
Spain 100, 90, 60 and 0% N/A Some non-prescription drugs are reimbursed Available
Italy Class A and H 100%, class C and C-bis 
0%
N/A No reimbursement for non-prescription drugs N/A
Portugal A 95%, B 69%, C 37%, D 15% N/A No reimbursement for non-prescription drugs Available
United Kingdom PPRS price negotiation Available No reimbursement for non-prescription drugs Available
Turkey Generally 41 and 28% discount. 18 and 
10% available for 20 year old medi-
cines and generics generally
Available No reimbursement for non-prescription drugs Available
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additional profit before making additional payments to 
the government for excessive profits. In turn, no com-
pany will be permitted any price increase to address lack 
of profitability unless its profits have fallen below 50% of 
allowable profit (ABPI Report 2014).
Greece applies price control for all medicines as Tur-
key. The price of imported and domestic medical prod-
ucts mustn’t exceed the minimum ex-factory prices in 
Europe. France applies direct price control for medi-
cines sold in hospitals, while reimbursement prices are 
determined by manufacturers and price controls are 
implemented for reimbursed medicines (Balçik and Kar-
savuran 2012).
It is highly difficult to keep the reimbursement prices 
‘lifetime’ under current circumstances. Prices set for the 
launch of the drug is maintained for a certain time and 
then the price is defined according to the price criteria 
again. Most countries prefer price cuts instead of increas-
ing the price of medicines. Direct price controls may lead 
to a retrenchment in drug prices by slowing down the 
increase in drug prices or by reducing the price of some 
drugs. However, the prices of medicines in the mentioned 
countries usually continued to increase. This increase is 
considered to be caused by the increase in the amount of 
medicine consumption or new molecules added to reim-
bursement lists (Mossialos et al 2004).
Conclusions
It is impossible to avoid the changes in the health care 
field all over the world. Technological developments, 
changes in the epidemiological patterns, increasement of 
the world population, rapid growth of society’s expecta-
tions and innovations in treatment processes cause health 
to be a area that is much more dynamic than the others. 
Keeping up with this major evolution has, accordingly, 
come to be the primary need of each country. Health area 
has strategic importance. By the virtue of this area, will a 
community be one that is healthy, more productive, self-
sufficient and sustainable.
It is also of great importance in our country for short, 
medium and long-term measures to be implemented for 
the sake of developing R & D and entrepreneurship eco-
system. R & D economic zones with special infrastruc-
ture, like in the example of other countries in the world, 
should be established in order help Turkey achieve her 
aim to develop new molecules and to produce drugs with 
a higher added value (TITCK 2014).
It can be seen that the R & D activities take an impor-
tant place in enhancing the market access of innovative 
medicines. It is also obvious that, for R & D activities, 
there is a need for strong public-pharmaceutical indus-
try-university collaboration. Regulations in this respect 
have undergone frequent changes in recent years but the 
impact of these changes should be examined in the long 
term. Further research into the relation between the box 
and value-based changes occurring in drug consumption 
and the changes in the regulations will also contribute to 
the arrangements to be made in the future.
A fixed rate of 1.9595 for Euro is applied between 
2009 till 2015 on reference pricing in Turkey. This rate 
was changed to 2,00 on June 2015 and with the latest 
price decision (2015); the value of 1 (one) Euro in Turk-
ish Liras to be used in the pricing of medicinal products 
for human use shall be designated upon multiplying with 
the adaptation coefficient designated as 70 percent of the 
average annual Euro value to be calculated upon taking 
into basis the daily indicative Euro foreign exchange sales 
rate realizations of the Central Bank of the Republic of 
Turkey declared on the Official Gazette of the previous 
year. (Decision on The Pricing Of Medicinal Products For 
Human Use 2015)
It is an undeniable fact that the long-standing policy 
of Turkish government to supply cheap drugs has many 
benefits for the budget in the short term. This can be seen 
clearly in the short term outcomes of the drug budget 
implementations.
Turkey is an important market for pharmaceutical sec-
tor with a population of over 75 million. Government 
Table 4 Reimbursement rates in Turkey Source: IMS Market Prognosis Sept. 2015; at ex-manufacturer price level, without 
rebates and discounts. Pharmaceutical Manufacturers Association of Turkey (IEIS 2016)
IMS Market Prognosis Sept. 2015; at ex-manufacturer price level, without rebates and discounts
Discount rates (TL) Original products Generic  
products (%)
Twenty year old product
Ex factory price ≤ 3.83 0% 0 0%
3.84 ≤ Ex factory 
price ≤ 7.32
Without generic With generic 10 0%
10% 10%
7.33 ≤ Ex factory 
price ≤ 11.02
11% (New molecules for first 
year) 31%
18% 18 Local With reference price Without reference price
10% 10% 10%
11.03 ≤ Ex factory price 11% (New molecules for first 
year) 41%
28% 28 28% 28% 40%
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policies that would be implemented in pricing and reim-
bursement processes may result positive effects to access 
of medicines in the short term and in the long term, but 
in order to prevent drug shortages and access to thera-
pies Turkish Government has been taking important 
decision such as localization of medicines and increasing 
euro value from 1,9595 to 2,1186 TL.
It is normal to observe a growth in health sector in a 
country that is growing in economic terms. However, 
considering the medicine particularly, the limits set by 
global budget did not seem to correlate with the eco-
nomic growth of Turkey. The global budget implementa-
tion has stopped end of 2014.
‘‘Price’’ stands out as an important element in the plans 
of pharmaceutical industry to realize new projects and 
investments to improve the competitiveness of the mar-
ket and make new investments. Pricing is expected to 
be based on an equitable, transparent and lucid system. 
Drug policies are expected to be in same way with the 
national policy of the country and the parameters of clar-
ity and efficiency, equity and cost should have an impact 
on all aspects of evaluations from the beginning.
Strict price controls appears to be effective on the point 
of costs. However, the cheapest price policy as the only 
policy may have negative consequences in other circum-
stances, and just because the price planning happen to 
be successful does not mean a similar success would be 
reached in total health expenditure as planned. It is a 
well-known fact that rational drug use comes before drug 
prices. So, supporting rational drug use is really impor-
tant. Focusing on demand side for efficiency, equity and 
quality improvement would give us rational drug use. 
Innovative drugs will increase drug expenditures in the 
future (Balçik and Karsavuran 2012).
Determining drug prices is not an easy decision after all 
and as it is directly affected by the internal dynamics of 
the country, no country can be expected to have the same 
conditions as any other country in this respect. However, 
as an emerging market, one of the priorities of Turkey 
aimed to be becoming the pioneer country of pharmaceu-
tical market as both a producer and an adminiştrator. This 
would definitely contribute to the general economy of the 
country in the long term. It is recommended that the fig-
ures which may be a burden on the economy in the short 
term be compensated in the long term with the invest-
ment agreements that will be signed with the industry. At 
this point, an example action that may be recommended 
is taking the average of the three lowest drug prices as 
reference, like in Greece; rather than picking the lowest 
price.
Greater cross-disciplinary interaction among econo-
mists, ethicists, and physicians can help to reduce the 
disjunction between innovation and access and can 
improve access and patient care. Increased interaction 
between experts in this multi-disciplinary area would 
result in better access to innovative medicines and treat-
ments for patient care together with better management 
of drug price settings (Lue et al. 2015).
Creating the inter-ministerial commission and making 
the pricing and reimbursement decisions through that 
commission, as seen in the other countries in our study, 
would minize problems between the institutions and lead 
to a healthier decision making process. It is thought that 
employing full-time experts will increase the working 
capacity and productivitiy of the commission. The pri-
mary objective here should be keeping the technical and 
scientific capacity of the Commission at the highest level, 
as in other countries. Then it would be feasible to draw 
clear lines between the health service provision, payer 
and decision-makers.
Key messages
1. Healthcare expenditures rises in all over world because 
of expensive therapies
2. Each country has specific regulations and pricing 
and reimbursement policies of medicines based on eco-
nomic situation reimbursement methods and market size
3. Reimbursement considerations in EU countries 
based on economical evaluations and budget impact
4. Pricing and reimbursement policies of medicines 
should be aimed to show compliance with efficient and 
sustainable health policies.
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